Comorbidities in patients with gout prior to and following diagnosis: Case-control study

Annals of the Rheumatic Diseases

Volumn 75, Issue 1, 2016, Pages 210-217

  Kuo, Chang Fu ^a,b   Grainge, Matthew J ^a   Mallen, Christian ^c   Zhang, Weiya ^a,d   Doherty, Michael ^a  

^a UNIVERSITY OF NOTTINGHAM   (United Kingdom)

^b CHANG GUNG MEMORIAL HOSPITAL   (Taiwan)

^c KEELE UNIVERSITY   (United Kingdom)

^d NOTTINGHAM CITY HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; AGED; ANEMIA; ARTICLE; CASE CONTROL STUDY; CHARLSON COMORBIDITY INDEX; CHRONIC LUNG DISEASE; COMORBIDITY; CONTROLLED STUDY; DEPRESSION; DISEASE ASSOCIATION; FEMALE; GOUT; HEALTH STATUS; HEMIPLEGIA; HUMAN; HYPERLIPIDEMIA; HYPOTHYROIDISM; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; MORTALITY; OSTEOARTHRITIS; PRIORITY JOURNAL; PSORIASIS; RISK ASSESSMENT; FACTUAL DATABASE; FOLLOW UP; RETROSPECTIVE STUDY; UNITED KINGDOM;

AGED; CASE-CONTROL STUDIES; COMORBIDITY; DATABASES, FACTUAL; FEMALE; FOLLOW-UP STUDIES; GOUT; HUMANS; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; UNITED KINGDOM;

EID: 84954227602     PISSN: 00034967     EISSN: 14682060     Source Type: Journal    
DOI: 10.1136/annrheumdis-2014-206410     Document Type: Article

References (74)

1. Kuo CF, Grainge MJ, Mallen C, et al. Rising burden of gout in the UK but continuing suboptimal management: a nationwide population study. Ann Rheum Dis 2015;74:661-7.
2. Zhang W, Doherty M, Pascual E, et al. EULAR evidence based recommendations for gout. Part I: Diagnosis. Report of a task force of the Standing Committee for International Clinical Studies Including Therapeutics (ESCISIT). Ann Rheum Dis 2006;65:1301-11.
3. Terkeltaub R. Update on gout: new therapeutic strategies and options. Nat Rev Rheumatol 2010;6:30-8.
4. Kuo CF, Yu KH, See LC, et al. Elevated risk of mortality among gout patients: a comparison with the national population in Taiwan. Joint Bone Spine 2011;78: 577-80.
5. Kuo CF, See LC, Luo SF, et al. Gout: an independent risk factor for all-cause and cardiovascular mortality. Rheumatology (Oxford) 2010;49:141-6.
6. Choi HK, Curhan G. Independent impact of gout on mortality and risk for coronary heart disease. Circulation 2007;116:894-900.
7. Puig JG, Martinez MA. Hyperuricemia, gout and the metabolic syndrome. Curr Opin Rheumatol 2008;20:187-91.
8. Kramer HJ, Choi HK, Atkinson K, et al. The association between gout and nephrolithiasis in men: the health professionals' follow-up study. Kidney Int 2003;64:1022-6.
9. Kramer HM, Curhan G. The association between gout and nephrolithiasis: the National Health and Nutrition Examination Survey III, 1988-1994. Am J Kidney Dis 2002;40:37-42.
10. Yu KH, Kuo CF, Luo SF, et al. Risk of end-stage renal disease associated with gout: a nationwide population study. Arthritis Res Ther 2012;14:R83.
11. Ab. Usbott RD, Brand FN, Kannel WB, et al. Gout and coronary heart disease: the Framingham Study. J Clin Epidemiol 1988;41:237-42.
12. Krishnan E, Baker JF, Furst DE, et al. Gout and the risk of acute myocardial infarction. Arthritis Rheum 2006;54:2688-96.
13. De Vera MA, Rahman MM, Bhole V, et al. Independent impact of gout on the risk of acute myocardial infarction among elderly women: a population-based study. Ann Rheum Dis 2010;69:1162-4.
14. Kuo CF, Yu KH, See LC, et al. Risk of myocardial infarction among patients with gout: a nationwide population-based study. Rheumatology (Oxford) 2013;52:111-17.
15. Clarson L, Chandratre P, Hider S, et al. Increased cardiovascular mortality associated with gout: a systematic review and meta-analysis. Eur J Prev Cardiol 2013. Published Online First: 26 Nov 2013. doi:10.1177/2047487313514895
16. Boffetta P, Nordenvall C, Nyren O, et al. A prospective study of gout and cancer. Eur J Cancer Prev 2009;18:127-32.
17. Kuo CF, Luo SF, See LC, et al. Increased risk of cancer among gout patients: a nationwide population study. Joint Bone Spine 2012;79:375-8.
18. Kuzell WC, Schaffarzick RW, Naugler WE, et al. Some observations on 520 gouty patients. J Chronic Dis 1955;2:645-69.
19. Durward WF. Letter: Gout and hypothyroidism in males. Arthritis Rheum 1976;19:123.
20. McAdams-Demarco MA, Maynard JW, Coresh J, et al. Anemia and the onset of gout in a population-based cohort of adults: atherosclerosis risk in Communities study. Arthritis Res Ther 2012;14:R193.
21. Zhang W, Doherty M, Bardin T, et al. EULAR evidence based recommendations for gout. Part II: management. Report of a task force of the EULAR Standing Committee for International Clinical Studies Including Therapeutics (ESCISIT). Ann Rheum Dis 2006;65:1312-24.
22. Khanna D, Fitzgerald JD, Khanna PP, et al. 2012 American College of Rheumatology guidelines for management of gout. Part 1: systematic nonpharmacologic and pharmacologic therapeutic approaches to hyperuricemia. Arthritis Care Res (Hoboken) 2012;64:1431-46.
23. Jordan KM, Cameron JS, Snaith M, et al. British Society for Rheumatology and British Health Professionals in Rheumatology guideline for the management of gout. Rheumatology (Oxford) 2007;46:1372-4.
24. Zhu Y, Pandya BJ, Choi HK. Comorbidities of gout and hyperuricemia in the US general population: NHANES 2007-2008. Am J Md 2012;125:679-87.
25. Annemans L, Spaepen E, Gaskin M, et al. Gout in the UK and Germany: prevalence, comorbidities and management in general practice 2000-2005. Ann Rheum Dis 2008;67:960-6.
26. Richette P, Clerson P, Perissin L, et al. Revisiting comorbidities in gout: a cluster analysis. Ann Rheum Dis 2015;74:142-7.
27. Walley T, Mantgani A. The UK General Practice Research Database. Lancet 1997;350:1097-9.
28. Herrett E, Thomas SL, Schoonen WM, et al. Validation and validity of diagnoses in the General Practice Research Database: a systematic review. Br J Clin Pharmacol 2010;69:4-14.
29. Jick H, Jick SS, Derby LE. Validation of information recorded on general practitioner based computerised data resource in the United Kingdom. BMJ 1991;302: 766-8.
30. Khan NF, Harrison SE, Rose PW. Validity of diagnostic coding within the general practice research database: a systematic review. Br J Gen Pract 2010;60:e128-36.
31. Jick SS, Kaye JA, Vasilakis-Scaramozza C, et al. Validity of the general practice research database. Pharmacotherapy 2003;23:686-9.
32. Meier CR, Jick H. Omeprazole, other antiulcer drugs and newly diagnosed gout. Br J Clin Pharmacol 1997;44:175-8.
33. Cea Soriano L, Rothenbacher D, Choi HK, et al. Contemporary epidemiology of gout in the UK general population. Arthritis Res Ther 2011;13:R39.
34. Feinstein AR. The pre-therapeutic classification of co-morbidity in chronic disease. J Chronic Dis 1970;23:455-68.
35. Charlson M, Szatrowski TP, Peterson J, et al. Validation of a combined comorbidity index. J Clin Epidemiol 1994;47:1245-51.
36. Deyo RA, Cherkin DC, Ciol MA. Adapting a clinical comorbidity index for use with ICD-9-CM administrative databases. J Clin Epidemiol 1992;45:613-19.
37. Khan NF, Perera R, Harper S, et al. Adaptation and validation of the Charlson Index for Read/OXMIS coded databases. BMC Fam Pract 2010;11:1.
38. Choi HK, Ford ES, Li C, et al. Prevalence of the metabolic syndrome in patients with gout: the Third National Health and Nutrition Examination Survey. Arthritis Rheum 2007;57:109-15.
39. Rho YH, Choi SJ, Lee YH, et al. The prevalence of metabolic syndrome in patients with gout: a multicenter study. J Korean Med Sci 2005;20:1029-33.
40. Chen SY, Chen CL, Shen ML. Manifestations of metabolic syndrome associated with male gout in different age strata. Clin Rheumatol 2007;26:1453-7.
41. Rathmann W, Funkhouser E, Dyer AR, et al. Relations of hyperuricemia with the various components of the insulin resistance syndrome in young black and white adults: the CARDIA study. Coronary Artery Risk Development in Young Adults. Ann Epidemiol 1998;8:250-61.
42. Vuorinen-Markkola H, Yki-Jarvinen H. Hyperuricemia and insulin resistance. J Clin Endocrinol Metab 1994;78:25-9.
43. Bhole V, Choi JW, Kim SW, et al. Serum uric acid levels and the risk of type 2 diabetes: a prospective study. Am J Med 2010;123:957-61.
44. Choi HK, De Vera MA, Krishnan E. Gout and the risk of type 2 diabetes among men with a high cardiovascular risk profile. Rheumatology (Oxford) 2008;47:1567-70.
45. Rodriguez G, Soriano LC, Choi HK. Impact of diabetes against the future risk of developing gout. Ann Rheum Dis 2010;69:2090-4.
46. Seminog OO, Goldacre MJ. Gout as a risk factor for myocardial infarction and stroke in England: evidence from record linkage studies. Rheumatology (Oxford) 2013;52:2251-9.
47. Krishnan E. Gout and the risk for incident heart failure and systolic dysfunction. BMJ Open 2012;2:e000282.
48. Abbott RD, Brand FN, Kannel WB, et al. Gout and coronary heart disease: the Framingham Study. J Clin Epidemiol 1988;41:237-42.
49. Lottmann K, Chen X, Schadlich PK. Association between gout and all-cause as well as cardiovascular mortality: a systematic review. Curr Rheumatol Rep 2012;14:195-203.
50. Richette P, Perez-Ruiz F, Doherty M, et al. Improving cardiovascular and renal outcomes in gout: what should we target? Nat Rev Rheumatol 2014;10:654-61.
51. Obermayr RP, Temml C, Knechtelsdorfer M, et al. Predictors of new-onset decline in kidney function in a general middle-European population. Nephrol Dial Transplant 2008;23:1265-73.
52. Obermayr RP, Temml C, Gutjahr G, et al. Elevated uric acid increases the risk for kidney disease. J Am Soc Nephrol 2008;19:2407-13.
53. Kuo CF, Luo SF, See LC, et al. Hyperuricaemia and accelerated reduction in renal function. Scand J Rheumatol 2011;40:116-21.
54. Yu TF. Nephrolithiasis in patients with gout. Postgrad Med 1978;63:164-70.
55. Yu T, Gutman AB. Uric acid nephrolithiasis in gout. Predisposing factors. Ann Int Med 1967;67:1133-48.
56. Shimizu T, Hori H. The prevalence of nephrolithiasis in patients with primary gout: a cross-sectional study using helical computed tomography. J Rheumatol 2009;36:1958-62.
57. Erickson AR, Enzenauer RJ, Nordstrom DM, et al. The prevalence of hypothyroidism in gout. Am J Med 1994;97:231-4.
58. Mariani LH, Berns JS. The renal manifestations of thyroid disease. J Am Soc Nephrol 2012;23:22-6.
59. Reynolds MD. Gout and hyperuricemia associated with sickle-cell anemia. Semin Arthritis Rheum 1983;12:404-13.
60. Roddy E, Zhang W, Doherty M. Are joints affected by gout also affected by osteoarthritis? Ann Rheum Dis 2007;66:1374-7.
61. Chhana A, Callon KE, Pool B, et al. The effects of monosodium urate monohydrate crystals on chondrocyte viability and function: implications for development of cartilage damage in gout. J Rheumatol 2013;40:2067-74.
62. Pascual E, Ordonez S. Orderly arrayed deposit of urate crystals in gout suggest epitaxial formation. Ann Rheum Dis 1998;57:255.
63. Merola JF, Wu S, Han J, Wu S, et al. Psoriasis, psoriatic arthritis and risk of gout in US men and women. Ann Rheum Dis 2015;74:1495-500.
64. Kuo CF, Yu KH, Luo SF, et al. Gout and risk of non-alcoholic fatty liver disease. Scand J Rheumatol 2010;39:466-71.
65. Bowman GL, Shannon J, Frei B, et al. Uric acid as a CNS antioxidant. J Alzheimers Dis 2010;19:1331-6.
66. Ames BN, Cathcart R, Schwiers E, et al. Uric acid provides an antioxidant defense in humans against oxidant- and radical-caused aging and cancer: a hypothesis. Proc Natl Acad Sci USA 1981;78:6858-62.
67. Kanellis J, Kang DH. Uric acid as a mediator of endothelial dysfunction, inflammation, and vascular disease. Semin Nephrol 2005;25:39-42.
68. Liu B, Shen Y, Xiao K, et al. Serum uric acid levels in patients with multiple sclerosis: a meta-analysis. Neurol Res 2012;34:163-71.
69. Kuo CF, See LC, Yu KH, et al. Significance of serum uric acid levels on the risk of all-cause and cardiovascular mortality. Rheumatology (Oxford) 2013;52:127-34.
70. Khokhar N. Gouty arthritis in chronic obstructive pulmonary disease. Arch Int Med 1982;142:838.
71. Zang YS, Fang Z, Li B. Gout-associated lung disease. Rheumatology (Oxford) 2012;51:756.
72. Creighton S, Miller R, Edwards S, et al. Is ritonavir boosting associated with gout? Int J STD AIDS 2005;16:362-4.
73. Wallace SL, Robinson H, Masi AT, et al. Preliminary criteria for the classification of the acute arthritis of primary gout. Arthritis Rheum 1977;20:895-900.
74. Kellgren JH, Jeffrey MR, Ball J, eds. The epidemiology of chronic rheumatism. Oxford: Blackwell, 1963.